Plv shrna egfp

Manufactured by VectorBuilder

PLV-shRNA-EGFP is a plasmid vector that expresses both short hairpin RNA (shRNA) and enhanced green fluorescent protein (EGFP). It is designed for gene knockdown studies.

Automatically generated - may contain errors

Lab products found in correlation

Mcherry t2a puro u6, by VectorBuilder (2 mentions) Human il 6, by R&D Systems (2 mentions) Thrombopoietin tpo, by R&D Systems (2 mentions)

Spelling variants of this product

PLV [shRNA]-EGFP-hACE-2 (2 citations)

2 protocols using plv shrna egfp

Lentiviral Transduction of Primary T-ALL and Cord Blood

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

Lentiviral vectors (pLV-shRNA-EGFP or mCherry:T2A:Puro-U6) was purchased (VectorBuilder) and wild-type and mutant ADAR1^E912A (pCDH-EF1-T2A-copGFP) were produced according to published protocol.^{33 (link)} All lentivirus was titer by transduction of HEK293T cells and efficiency was assessed by p24 ELISA and RT-qPCR of the 5′ LTR region. Lentiviral transduction of primary T-ALL or cord blood samples was performed at a MOI of 100–200. The cells were cultured for 3–4 days in 96-well plate (2X10⁵-5X10⁵ cells per well) containing StemPro (Life Technologies) media supplemented with human IL-6, stem cell factor (SCF), Thrombopoietin (TPO) and FLT3 (all from R&D Systems). For T-ALL cell lines, the cells were transduced at a MOI of 20–50 in culture media.

Rivera M., Zhang H., Pham J., Isquith J., Zhou Q.J., Balaian L., Sasik R., Enlund S., Mark A., Ma W., Holm F., Fisch K.M., Kuo D.J., Jamieson C, & Jiang Q. (2024). Malignant A-to-I RNA editing by ADAR1 drives T cell acute lymphoblastic leukemia relapse via attenuating dsRNA sensing. Cell reports, 43(2), 113704.

+ Open protocol

+ Expand

Lentiviral Transduction of T-ALL and Cord Blood

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

Lentiviral vectors (pLV-shRNA-EGFP or mCherry:T2A:Puro-U6) was purchased (VectorBuilder) and wild-type and mutant ADAR1^E912A (pCDH-EF1-T2A-copGFP) were produced according to published protocol ^{25 (link)}. All lentivirus was titer by transduction of HEK293T cells and efficiency was assessed by p24 ELISA and RT-qPCR of the 5’ LTR region. Lentiviral transduction of primary T-ALL or cord blood samples was performed at a MOI of 100–200. The cells were cultured for 3–4 days in 96-well plate (2X10⁵-5X10⁵ cells per well) containing StemPro (Life Technologies) media supplemented with human IL-6, stem cell factor (SCF), Thrombopoietin (TPO) and FLT3 (all from R&D Systems). For T-ALL cell lines, the cells were transduced at a MOI of 20–50 in culture media.

Rivera M., Zhang H., Pham J., Isquith J., Zhou Q.J., Sasik R., Mark A., Ma W., Holm F., Fisch K.M., Kuo D.J., Jamieson C, & Jiang Q. (2023). Malignant A-to-I RNA editing by ADAR1 drives T-cell acute lymphoblastic leukemia relapse via attenuating dsRNA sensing. Research Square.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!